Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 5

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  cystatin C
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Content available remote

Cystain C and neuropeptid Y levels in brain tissues after experimental subarachnoid hemorrhage

100%
Açıkgöz Ş., Can M., Güven B., Edebali N., Barut F., Büyükuysal Ç., Tekin İ., Açıkgöz B.
|
2014
|
vol. 61
|
issue 4
825-828
EN
The aim of this study was to investigate the changes in the levels of cystatin C, which protects neurodegeneration in the central nervous system with the inhibition of cysteine protease and by inducing autophagy in the pathogenesis of cerebral vasospasm and levels of vasoconstrictive neuropeptid Y (NPY) in the brain tissue homogenates of rat model of subarachnoid hemorrhage (SAH). Three experimental groups were used: Day 2 and Day 7 groups after SAH, and also a control group. There were seven Wistar albino rats in each group. SAH was accomplished by transclival basilar artery puncture. Rat cystatin C, rat NPY were determined with ELISA in brain tissue homogenates. Day 2 group showed significantly enhanced cystatin C values in comparision with the control group (P=0.048). NPY levels between the Day 2 and Day 7 groups and the control groups were not significantly different (P=0.315). In histopathological examination, there was less neuronal loss in the Day 2 group than in the Day 7 group. Regarding our results, it would be more valuable to measure NPY levels in specific brain areas. The increased cystatin C levels on the second day after SAH is probably a pathophysiologic mechanism to organize protease activity.
2
Content available remote

Determinants of plasma homocysteine in coal miners

88%
Mungan A., Can M., Kıran S., Açıkgöz Ş., Güven B.
|
2013
|
vol. 60
|
issue 3
443-449
EN
Aim: Several studies suggest that coal miners are under risk of severe health problems such as cardiovascular, pulmonary, neurological, renal, hematological and musculoskeletal disorders. However, there are limited data on biochemical changes in underground workers. In our study we aimed to evaluate the association between serum homocysteine (Hcy), vitamin B12, cystatin C and folate levels in the blood of underground coal miners. Materials and Methods: Eighty one coal miners who work as underground or surface workers were recruited into our study. The study population was divided into two groups: the surface worker group (control group, n=33) and the underground worker group (n=48). The folate, vitamin B12, Hcy, cystatin C levels and body mass indexes (BMI) of both groups were measured and compared. Serum folate, Hcy and vitamin B12 levels were measured with a competitive chemiluminescence immunassay. Serum levels of cystatin C were determined by the latex particle-enhanced turbidimetric method using a cystatin C kit. Urea values were measured with a kinetic method on an automated analyzer. Results: There were no statistically significant differences between the underground workers and surface workers in the urea, cystatin C and vitamin B12 levels. High serum Hcy levels and low folate levels were found in underground workers compared with those in surface workers. The correlation between Hcy and folate levels was also statistically significant. Similarly, there was also a significant correlation between Hcy and vitamin B12, and between Hcy and cystatin C levels. Conclusions: Elevated Hcy levels may be associated with underground working but further research is necessary to understand the relation between elevated Hcy and increased prevalence of health problems in coal miners.
3
Publication available in full text mode
Content available

24-hour blood pressure monitoring and renal function evaluation at the predicted term of delivery in prematurely born children

88%
Gilarska M., Wolińska D., Kwinta P., Gilarska M., Wolińska D., Kwinta P.
Folia Medica Cracoviensia
|
2021
|
vol. 61
|
issue 3
4
Content available remote

Serum Cystatin C in Relation to Fat Mass Loss After Bariatric Surgery"

88%
Śledziński T., Proczko-Markuszewska M., Kaska Ł., Stefaniak T., Świerczyński J.
Polish Journal of Surgery
|
2012
|
vol. 84
|
issue 4
202-207
EN
Serum cystatin C concentration, generally accepted as renal function marker, is associated with cardiovascular risk and metabolic syndrome. Recent studies indicate that cystatin C increases in human obesity and that adipose tissue contributes to enhanced serum cystatin C concentration in obese subjects.The aim of the study was to assess whether a reduction in body and fat mass after bariatric surgery has any impact on serum cystatin C concentrations.Material and methods. Serum from 27 obese patients were tested before and 6 months after bariatric surgery. Twenty healthy subjects with normal body weight served as controls. Serum cystatin C concentrations were assayed by ELISA.Results. Serum cystatin C concentrations were significantly higher in obese patients compared with non-obese subjects. Decrease of body and fat mass after bariatric surgery resulted in improvement of several parameters associated with cardiovascular risk and metabolic syndrome, like serum lipids, blood pressure and insulin sensitivity. Surprisingly the mean postoperative serum cystatin C concentration was not significantly different from that before surgery. Serum creatinine and GFR also remained unchanged.Conclusion. The results presented here suggest that serum cystatin C concentration is not tightly associated with body and fat mass loss in obese patients after bariatric surgery.
5
Publication available in full text mode
Content available

Ocena czynności nerek u dzieci leczonych metodą ESWL – doniesienie wstępne

63%
Straż-Żebrowska E., Jung A., Jobs K., Bochniewska V.
Pediatria i Medycyna Rodzinna
|
2010
|
vol. 6
|
issue 1
48-53
EN
Urolithiasis is the condition where calculi are formed in the urinary tract in case of impaired balance between concentration of inhibitors and promoters of crystallization. Actually, there is observed growing incidence of nephrolithiasis in the societies of highly industrialized countries also in the paediatric population. It applies even up to 5% of this population, and growing group are children in infancy. There are conservative and surgical methods of treatment. Suitable for conservative treatment are usually stones up to 5 mm in diameter, larger deposits require invasive procedures. Among surgical methods there can be distinguished relatively less invasive such as: ESWL (extracorporeal shock wave lithotripsy), PCNL (percutaneous nephrolithotomy), URSL (ureteroscopic lithotripsy). Surgical treatment is nowadays much less common. ESWL procedure by the action of shock wave leads to calculi disintegration. Aim: Method safety assessment in the aspect of renal function at children with urolithiasis treated with ESWL method. Material and methods: Survey covered 16 children (7 male and 9 female) aged 2.5 to 17.5 years (mean age 9.5). Forty-eight hours before performing ESWL procedure, there were blood cell count, markers of inflammation, serum renal parameters concentration (creatinine, urea, cystatin C) and coagulogram determined. Creatinine and cystatin C clearance was calculated. Arterial blood pressure was measured. Reassessment compiled on the basis of the same parameters were made after the period of 1 to 5 months (mean time 2.8 months) after the ESWL treatment. Results: Mean concentration of cystatin C, creatinine, urea and values of creatinine clearance, cystatin C clearance, systolic and diastolic blood pressure before and after ESWL procedure showed no statistically significant differences. Statistically significant reduction of microalbuminuria was found. Conclusions: On the basis of testing carried out, the ESWL procedure was preliminarily found as an effective and safe method of urolithiasis treatment.
PL
Kamica układu moczowego jest chorobą polegającą na tworzeniu się złogów w drogach moczowych w momencie zaburzenia równowagi pomiędzy promotorami i inhibitorami krystalizacji. Obecnie obserwuje się narastanie częstości występowania kamicy w społeczeństwach krajów wysoko uprzemysłowionych, w tym również w populacji dziecięcej. Problem ten dotyczy nawet 5% tej populacji, a coraz większą grupę stanowią dzieci w okresie niemowlęcym. Wśród metod leczenia wyróżniamy postępowanie zachowawcze lub zabiegowe. Leczeniu zachowawczemu najczęściej poddaje się złogi o średnicy do 5 mm, większe wymagają zastosowania metod inwazyjnych. Wśród metod zabiegowych wyróżniamy metody stosunkowo mało inwazyjne, takie jak: ESWL (kruszenie złogów falą generowaną pozaustrojowo), PCNL (przezskórna nefrolitotrypsja), URSL (endoskopowa litotrypsja). Obecnie znacznie rzadziej stosowane jest leczenie operacyjne. Zabieg ESWL poprzez działanie fali uderzeniowej powoduje dezintegrację złogu. Cel: Ocena bezpieczeństwa metody w aspekcie funkcji nerek u dzieci leczonych z powodu kamicy układu moczowego metodą ESWL. Materiał i metody: Badaniem objęto 16 dzieci (7 chłopców i 9 dziewczynek) w wieku od 2,5 do 17,5 roku (średni wiek 9,5 roku). W ciągu 48 godzin przed wykonaniem zabiegu ESWL oznaczano morfologię krwi, wykładniki stanu zapalnego, stężenie parametrów nerkowych w surowicy (kreatynina, mocznik, cystatyna C), koagulogram. Wyliczano klirensy dla kreatyniny oraz cystatyny C. Mierzono wartości ciśnienia tętniczego. Ponownej oceny czynności nerek w oparciu o te same parametry dokonano w okresie od 1 do 5 miesięcy (średni czas 2,8 miesiąca) po zabiegu. Wyniki: Średnie stężenia cystatyny C i kreatyniny oraz wartości klirensów kreatyniny i cystatyny C, mocznika, wartości ciśnienia skurczowego i rozkurczowego nie wykazały istotnych statystycznie różnic przed i po zabiegu ESWL. Stwierdzono statystycznie znamienne zmniejszenie mikroalbuminurii. Wnioski: Na podstawie oceny wykonanych badań stwierdzono wstępnie, że metoda ESWL jest skutecznym i bezpiecznym sposobem leczenia kamicy układu moczowego.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.